KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

BioNTech SE (BNTX) EBT Margin: 2018-2025

Historic EBT Margin for BioNTech SE (BNTX) over the last 7 years, with Sep 2025 value amounting to 1.63%.

  • BioNTech SE's EBT Margin fell 1112.00% to 1.63% in Q3 2025 from the same period last year, while for Sep 2025 it was -16.23%, marking a year-over-year decrease of 592.00%. This contributed to the annual value of -24.63% for FY2024, which is 5569.00% down from last year.
  • According to the latest figures from Q3 2025, BioNTech SE's EBT Margin is 1.63%, which was up 101.05% from -154.41% recorded in Q2 2025.
  • BioNTech SE's 5-year EBT Margin high stood at 169.74% for Q3 2021, and its period low was -626.11% during Q2 2024.
  • For the 3-year period, BioNTech SE's EBT Margin averaged around -116.50%, with its median value being 1.63% (2025).
  • Its EBT Margin has fluctuated over the past 5 years, first plummeted by 38,031bps in 2024, then soared by 47,170bps in 2025.
  • Quarterly analysis of 5 years shows BioNTech SE's EBT Margin stood at 85.20% in 2021, then plummeted by 1,105bps to 74.16% in 2022, then plummeted by 2,931bps to 44.84% in 2023, then crashed by 1,953bps to 25.31% in 2024, then tumbled by 1,112bps to 1.63% in 2025.
  • Its EBT Margin stands at 1.63% for Q3 2025, versus -154.41% for Q2 2025 and -243.65% for Q1 2025.